It is illegal to post this copyrighted PDF on any website. Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015

Taeho Greg Rhee, PhD, MSW^{a,b,*}; Somaia Mohamed, MD, PhD^{c,d,e}; and Robert A. Rosenheck, MD^{c,d,e}

ABSTRACT

Objective: A recent moderately long-term study found an antipsychotic to be more effective than an antidepressant as the next-step treatment of unresponsive major depressive disorder (MDD). It is thus timely to examine recent trends in the pharmacoepidemiology of antipsychotic treatment of MDD.

Methods: Data from the 2006–2015 National Ambulatory Medical Care Survey, nationally representative samples of office-based outpatient visits in adults with MDD (*ICD-9-CM* codes 296.20–296.26 and 296.30–296.36) (n = 4,044 unweighted), were used to estimate rates of antipsychotic prescribing over these 10 years. Multivariable logistic regression analysis identified demographic and clinical factors independently associated with antipsychotic use in MDD.

Results: Antipsychotic prescribing for MDD increased from 18.5% in 2006–2007 to 24.9% in 2008–2009 and then declined to 18.9% in 2014–2015. Visits with adults 75 years or older showed the greatest decline from 27.0% in 2006–2007 to 10.7% in 2014–2015 (OR for overall trend = 0.73; 95% CI, 0.56–0.95). The most commonly prescribed antipsychotic agents were aripiprazole, olanzapine, quetiapine, and risperidone. Antipsychotic prescription was associated with being black or Hispanic, having Medicare among adults under 65 years or Medicaid as a primary source of payment, and receiving mental health counseling, 3 or more concomitant medications, and diagnosis of cannabis use disorder (P < .01).

Conclusions: Antipsychotics, prescribed for about one-fifth of adults with MDD, increased and then declined from 2006 to 2015, reflecting, first, FDA approval and then concern about adverse effects in the elderly. Future research should track evolving trends following the publication of evidence of greater long-term effectiveness of antipsychotic than antidepressant next-step therapy in adults with MDD.

J Clin Psychiatry 2018;79(2):17m11970

To cite: Rhee TG, Mohamed S, Rosenheck RA. Antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: national trends from 2006 to 2015. *J Clin Psychiatry*. 2018;79(2):17m11970.

To share: https://doi.org/10.4088/JCP.17m11970 © Copyright 2018 Physicians Postgraduate Press, Inc.

^aSection of Geriatrics, Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut

^bYale Center for Outcomes Research and Evaluation (CORE), Yale-New Haven Hospital, New Haven, Connecticut

^cDepartment of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut

^dVeterans Affairs (VA) New England Mental Illness Research, Education and Clinical Centers (MIRECC), West Haven, Connecticut

^eVeterans Affairs (VA) Connecticut Healthcare System, West Haven, Connecticut

*Corresponding author: Taeho Greg Rhee, PhD, MSW, Yale University School of Medicine, 333 Cedar St, PO Box 208025, New Haven, CT 06520 (taeho.rhee@yale.edu). **M**ajor depressive disorder (MDD) is one of the most common mental disorders, affecting 16.1 million US adults in 2015.¹ MDD is a chronic, recurring, and debilitating psychiatric disorder² and remains one of the main causes of disability and comorbidity globally.³ Conventionally, antidepressants have long been the first-line pharmacologic therapy for MDD.^{2,4} Despite the availability of numerous antidepressants, approximately two-thirds of individuals with MDD fail to achieve remission from a first antidepressant trial.^{5,6} Patients who fail 2 trials are considered to have treatment-resistant depression.⁷

For patients who do not respond to antidepressants, switching to another antidepressant or augmentation with either an additional antidepressant or a non-antidepressant agent is common practice and is recommended in most guidelines.^{8–10} Augmentation and adjunctive treatment of antidepressants with 4 second-generation antipsychotics are the only pharmacologic alternatives to antidepressants that have been approved by the US Food and Drug Administration (FDA) for this purpose.^{11,12} Aripiprazole was the first agent approved by the FDA as an adjunctive treatment to antidepressants for MDD on November 1, 2007.¹³ Subsequently, quetiapine and olanzapine/fluoxetine combination were approved on December 4 and 14, 2009, respectively, and brexipiprazole was approved on July 10, 2015.^{13,14}

Despite the positive evidence from placebo-controlled randomized trials (RCTs) of antipsychotic efficacy in treating nonresponsive MDD, until recently, there had been no effectiveness studies comparing antipsychotic treatment to either switching to a new antidepressant or adding an additional antidepressant. However, the recent multisite VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) study^{10,15} reported the results of an RCT showing that augmentation of antidepressant treatment with an antipsychotic agent, aripiprazole, was significantly more effective in promoting remission (ie, virtual lack of depressive symptoms) than switching to a new antidepressant (bupropion) and significantly more effective in promoting response (reduction of symptoms by 50%) than either switching to another antidepressant or adding another antidepressant.¹⁰ Because atypical antipsychotics carry well-known risks for adverse events (eg, extrapyramidal side effects, tardive dyskinesia, weight gain, diabetes, morbidity, or mortality),^{13,16} it is notable that aripiprazole treatment in the VAST-D study was

Rhee et al

It is illegal to post this copyrighted PDF on any website. Ninth Edition, Clinical Modification (ICD-9-CM) diagnostic

- Although recent research supports the effectiveness of antipsychotics in unresponsive major depressive disorder (MDD), little is known about the national prescribing trends for antipsychotics in MDD.
 - FDA-approved second-generation antipsychotics are prescribed at about 1 in 5 office-based visits at which MDD is diagnosed, with little change in recent years.
 - Pharmacosurveillance data are needed to provide better information on long-term effectiveness and safety of antipsychotics for MDD.

associated with greater weight gain than other treatments while bupropion was associated with greater anxiety. Since the results of VAST-D may be taken as generally supportive of greater antipsychotic use in MDD, it is timely to review trends in antipsychotic prescribing in recent years for the management of MDD in ambulatory care settings. To our knowledge, there have been only 2 pharmacoepidemiologic studies of antipsychotic prescribing patterns in MDD.^{14,17} One study based on Medicaid Analytic eXtract (MAX) data from 2001 to 2010 found that 14% of patients with MDD were started on an antipsychotic medication within 1 year following onset of MDD.¹⁴ Another study found that 20.6% of veterans with MDD treated in the Veterans Health Administration (VHA) in fiscal year 2007 received antipsychotic medications.¹⁷ These studies, however, focused only on Medicaid beneficiaries¹⁴ or VHA patients,¹⁷ used data from many years ago, and did not address time trends in prescribing patterns over the last decade.

To fill in existing gaps in the literature, we address the following research questions: (1) What are the national prevalence rates of antipsychotic prescriptions from 2006 to 2015 in visits in which MDD was diagnosed? (2) What particular antipsychotic medications were most commonly prescribed from 2006 to 2015 in visits with MDD? and, finally, (3) What demographic and clinical characteristics are associated with antipsychotic prescription in visits with MDD? This is, thus, the first descriptive study to investigate national trends in antipsychotic prescribing patterns among patients with MDD seen in office-based outpatient settings and provides a benchmark for tracking future use of antipsychotics in adults with MDD in light of recently published research.

METHODS

Data Source and Study Sample

We used data from the 2006 to 2015 National Ambulatory Medical Care Survey (NAMCS), administrated by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC).¹⁸ The NAMCS is an annual, cross-sectional survey of visits to officebased physicians in outpatient settings.¹⁸ The NAMCS was designed to represent office-based outpatient care at the national level. The NAMCS collects up to 3 clinical diagnoses using the *International Classification of Diseases*, **EXAMPLE 21** An origination (PCD-9-CM) diagnostic codes. Using this information, we selected visits made by adults 18 years or older who were diagnosed with MDD (296.20–296.26 and 296.30–296.36) (n = 4,464 unweighted). We excluded those diagnosed with bipolar disorders (296.0X, 296.1X, 296.40–296.80), schizophrenia (295.XX), and other psychoses (297.XX–299.XX) (n = 113 unweighted). We further excluded observations with all missing covariates (n = 307 unweighted), which were missing at random, leaving a final sample size of 4,044. Because publicly available deidentified data were used, the research procedure for this study was exempted from the Institutional Review Board (2000021850) at Yale School of Medicine. Further details of the survey, including descriptions, questionnaires, sampling methodology, and datasets, are publicly available on the NAMCS website.¹⁹

Measures

Antipsychotics. The NAMCS collects up to 8 medications prescribed in 2006–2011, up to 10 medications in 2012–2013, and up to 30 medications in 2014-2015. For consistency across years, we considered only the first 8 medications. Using the 2017 American Hospital Formulary Service (AHFS) Compendium²⁰ and previous studies,^{17,21} we identified prescribed antipsychotic medications using generic names. We included 11 typical, or first-generation, antipsychotics (haloperidol, chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, thiothixene, loxapine, molindone, pimozide) and 10 atypical, or secondgeneration, antipsychotics (aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone). We constructed a binary variable (yes/no) for overall antipsychotic prescription status.

Covariates. On the basis of previous studies,^{4,17,22} we identified a number of covariates. We included the following demographic variables: age, gender, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or other), region (Northeast, Midwest, South, or West), primary source of payment (private, Medicare (<65 years), Medicare $(\geq 65$ years), Medicaid, or other), reason for visit (acute problem, routine chronic problem, preventive care, or preor postsurgery care), and repeat of visits within the past 12 months (none, 1-2, 3-5, or 6+). For clinical characteristics, we included the following variables: physician specialty (primary care, psychiatry, or other), metropolitan statistical area status (yes/no), psychotherapy provided (yes/no), mental health counseling other than psychotherapy provided (yes/no), time spent with a doctor (<15, 15–20, 21–30, or >30 min), antidepressants prescribed (yes/no),⁴ number of chronic conditions (1, 2-3, or 4+), and number of medications (0-3, -3)4-5, or 6+). The number of chronic conditions was based on 14 chronic conditions (yes/no) collected by the NAMCS (eg, arthritis, congestive heart failure, and diabetes). We also constructed variables identifying comorbid psychiatric disorders (dementia, posttraumatic stress disorder, anxiety disorders, adjustment disorders, personality disorders, **It is illegal to post this copyrighted PDF on any website** Table 1. Selected Characteristics (weighted column %) of US Adults 18 Years and Older With Major Depressive Disorder (MDD) by Antipsychotic Prescription Status in Office-Based Outpatient Settings, 2006–2015 National Ambulatory Medical Care Survey

Antipsychotic			Antipsychotic						
	Prescription (%)			Р		Prescription (%)			Р
Characteristic	No	Yes	Total	Value ^a	Characteristic	No	Yes	Total	Value ^a
Sample size (row %)					MSA status				
Unweighted sample (n)	80.3 (3,249)	19.7 (795)	100 (4,044)		MSA	94.0	90.7	93.4	.008
Weighted visits (N)	80.0	20.0	100		Non-MSA	6.0	9.3	6.6	
5	(6,380,114)	(1,596,826)	(7,976,941)		Psychotherapy provided				
Age, y	(, , , , , , , , , , , , , , , , , , ,	() , ,	())		Yes	40.7	40.9	40.7	.954
18–44	36.9	35.0	36.5	.220	No	59.3	59.1	59.3	
45–64	47.0	52.2	48.0		Mental health counseling provided				
65–74	10.3	7.9	9.8		Yes	22.8	32.5	24.8	<.001
75+	5.8	4.9	5.6		No	77.2	67.5	75.3	
Gender					Time spent with doctor, min		0710	, 515	
Female	67.0	63.3	66.2	.186	<15	9.9	9.7	9.8	.064
Male	33.0	36.7	33.8		15-20	30.6	35.4	31.6	.001
Race/ethnicity					21-30	26.7	29.9	27.4	
Non-Hispanic white	81.4	73.0	79.7	<.001	> 30	32.8	25.5	31.2	
Non-Hispanic black	5.2	8.8	5.9		Antidepressants prescribed	52.0	25.1	51.2	
Hispanic	10.0	15.5	11.1		Yes	80.9	85.9	81.9	041
Other ^b	3.4	2.7	3.3		No	19.1	14 1	18.1	.041
Region					Multiple chronic conditions	15.1	1-1.1	10.1	
Northeast	24.5	26.2	24.9	.030	1	64.3	62.3	63.9	156
Midwest	15.4	18.3	16.0		2_3	28.3	32.5	29.0	.150
South	30.8	34.5	31.5		2-5	20.5	56	20.0	
West	29.3	20.9	27.6		Number of medications	7.5	5.0	7.1	
Primary source of payment					~ 2	567	22.2	10.5	< 001
Private	52.9	39.0	50.1	<.001	3_5	34.2	23.5	49.5	<.001
Medicare (<65)	7.8	15.4	9.3		5-5	0.0	1/1	10.4	
Medicare (≥65)	10.8	9.8	10.6		Ot	9.0	14.1	10.2	
Medicaid	9.0	17.2	10.6		Domontia	06	0.2	0.6	207
Other ^c	19.5	18.7	19.4			0.0	0.5	5.0	.597
Reason for visit					Anvioty	20.4	0.1 24.1	2.9	.033
Acute problem	9.2	5.5	8.4	.033	Adjustment disorders	20.4	24.1	21.2	.122
Routine chronic problem	88.1	92.2	88.9		Aujustment disorders	1.1	0.2	0.9	.001
Preventive care	0.2	0.0	0.2		Depressive disorders	2.4	4.2	2.0	.050
Pre- or postsurgery	2.5	2.3	2.5		other than MDD	5.1	4.5	5.5	.557
Repeat of visits in the past 12	2 months				Mild cognitive	0.1	0.0	0.1	525
0 visit	2.1	1.2	1.9	<.001	imagina	0.1	0.0	0.1	.555
1–2 visits	21.2	15.5	20.1		Impairment	ام مناطقة ما ا			
3–5 visits	32.6	26.2	31.3			sychiatric di	sorders	2.2	227
6+ visits	44.1	57.1	46.7		Alcohol	3.0	3.9	3.2	.337
Physician specialty					Opiates	0.7	0.6	0.7	.560
Primary care	13.6	4.8	11.9	<.001	Cornehia	0.1	0.3	0.1	.308
Psychiatry	83.9	93.1	85.7		Carinabis	0.3	1.2	0.5	<.001
Other specialties ^d	2.5	2.0	2.4		BarDiturates	0.0	0.0	0.0	.579
					Ampnetamines	0.1	0.2	0.2	.698
					Hallucinodens	0.0	0.0	0.0	

^aCompares proportion differences by antipsychotic prescription status using a weight-corrected Pearson χ^2 statistic.

^bIncludes Asians, American Indian/Alaska Natives, Native Hawaiian or Other Pacific Islanders, and other mixed races.

^cIncludes worker's compensation, self-pay, no charge, and others.

^dIncludes general surgery, obstetrics/gynecology, orthopedic surgery, cardiovascular diseases, dermatology, urology, neurology, ophthalmology, otolarvngology, and others.

Abbreviations: MDD = major depressive disorder, MSA = metropolitan statistical area, PTSD = posttraumatic stress disorder.

depressive disorders other than MDD, and mild cognitive impairment) and 7 specific substance use psychiatric disorders (alcohol, opiates, cocaine, cannabis, barbiturates, amphetamines, and hallucinogens) using the *ICD-9-CM* diagnostic codes.²¹

Data Analysis

First, we examined the extent to which patients with MDD who were prescribed antipsychotic medication differed on demographic and clinical characteristics from those not prescribed such medication. We used design-based *F* tests (ie, weight-corrected Pearson χ^2 statistics) to test differences by the antipsychotic prescribing trends over time from 2006 to 2015.

After estimating the overall proportion of visits in which antipsychotics were prescribed, we performed stratified analyses for MDD with psychotic features (*ICD-9-CM* codes 296.24 and 296.34) and without psychotic features, as well as by age, gender, race/ethnicity, primary source of payment, and physician specialty. In trend analyses, we combined years into 2-year intervals, assigning values ranging from 1 to 5 (1 = 2006 - 2007, 2 = 2007 - 2008, etc). We transformed this variable by subtracting 1 and dividing by 4, resulting in values between 0 and 1. This allowed us to interpret the odds ratio (OR) as the change in odds of receiving a prescription for an antipsychotic across the 10-year period.

Third, we estimated prevalence of each antipsychotic agent prescribed over time by antipsychotic classification

Rhee et al

It is illegal to post this copyrighted PDF on any website

Table 2. Stratified Analysis of Visit Proportions (weighted column %) in Which Antipsychotics Were Prescribed Among US Adults 18 Years and Older With Major Depressive Disorder (MDD), 2006–2015 NAMCS

	Years (%)						Trend (2006–2015)			
Variable	2006-2007	2008-2009	2010-2011	2012-2013	2014-2015	Total	OR	95% CI	P Value	
Total proportion of visits with antipsychotics in MDD	18.5	24.9	20.5	17.6	18.9	20.0	0.96	0.88-1.04	.326	
Visits with antipsychotics in MDD with nonpsychotic features	15.9	22.0	17.8	16.7	16.3	17.7	0.97	0.89–1.05	.425	
Visits with antipsychotics in MDD with psychotic features	68.4	83.6	55.8	52.1	75.2	66.9	0.96	0.74–1.26	.786	
Total proportion of visits in which antidepressants were prescribed along with antipsychotics	18.5	24.5	22.5	18.5	20.9	21.0	0.99	0.91–1.08	.891	
Visits in which antidepressants were prescribed along with antipsychotics in MDD with nonpsychotic features	16.1	21.7	19.6	17.3	17.7	18.5	0.99	0.91–1.08	.850	
Visits in which antidepressants were prescribed along with antipsychotics in MDD with psychotic features	70.8	82.8	67.4	63.8	75.2	72.6	0.98	0.73–1.33	.913	
Age, y										
18–44	14.1	25.4	22.7	14.6	18.4	19.2	0.98	0.88–1.10	.761	
45–64	20.5	25.1	21.2	21.3	20.9	21.7	0.98	0.87–1.11	.778	
65–74	20.7	24.2	8.3	16.0	15.7	16.1	0.90	0.67–1.22	.504	
75+	27.0	21.9	19.8	10.9	10.7	17.5	0.73	0.56–0.95	.019	
Gender										
Female	17.1	22.6	21.9	15.6	18.6	19.1	0.97	0.88–1.08	.595	
Male	21.7	30.2	17.9	22.0	19.6	21.8	0.93	0.80-1.08	.331	
Race/ethnicity										
Non-Hispanic white	17.2	22.9	17.9	16.4	17.9	18.3	0.97	0.89–1.06	.470	
Non-Hispanic black	35.1	43.1	31.9	21.9	16.9	29.8	1.09	0.54–0.99	.044	
Hispanic	22.7	28.0	30.3	26.4	31.4	28.0	1.08	0.78–1.48	.646	
Other ^a	12.5	16.3	18.8	11.5	19.2	16.6	1.09	0.72–1.64	.686	
Source of payment										
Private	11.7	20.7	14.2	14.3	17.7	15.9	1.06	0.93–1.20	.395	
Medicare (< 65)	35.9	42.8	37.4	24.6	21.6	33.0	0.78	0.61–1.00	.054	
Medicare (≥65)	30.9	25.3	13.6	16.3	13.5	18.6	0.77	0.59–1.00	.049	
Medicaid	31.7	31.7	34.3	26.0	39.2	32.3	1.03	0.85–1.26	.736	
Other ^b	20.6	18.2	22.4	19.3	16.6	19.3	0.95	0.81–1.11	.491	
Physician specialty										
Primary care	6.4	20.9	7.2	2.8	7.7	8.2	0.79	0.55–1.13	.191	
Psychiatry	20.0	25.6	22.4	20.4	20.4	21.8	0.97	0.89–1.06	.533	
Other ^c	3.0	4.6	22.5	23.8	15.8	16.9	1.20	0.74–1.94	.458	
Sample size								Total		
Unweighted sample	632	671	782	1,318	641			4,044	ł	
Weighted visits	1,412,102	1,458,356	1,726,968	1,545,536	1,833,979			7,976,941		

^alncludes Asians, American Indian/Alaska Natives, Native Hawaiian or Other Pacific Islanders, and other mixed races.

^bIncludes worker's compensation, self-pay, no charge, and others.

^qIncludes general surgery, obstetrics/gynecology, orthopedic surgery, cardiovascular diseases, dermatology, urology, neurology, ophthalmology,

otolaryngology, and others.

and generic names with summary data for first- and secondgeneration antipsychotics. We again used design-based Ftests to investigate the differences in patterns across years. Lastly, we ran a multivariable-adjusted logistic regression analysis to identify demographic and clinical factors independently associated with antipsychotics prescriptions. In this analysis, we included only those variables that had significance differences by antipsychotic prescription status at the level of P < .01. We used Stata 13.1^{23} for all analyses, and we employed the *svy* commands to account for the complex survey sampling design of the NAMCS (ie, unequal probability of selection, clustering, and stratification).

RESULTS

Selected Characteristics of the Sample

Altogether, 20.0% of visits with a diagnosis of MDD involved prescription of an antipsychotic. Table 1 presents demographic and clinical characteristics of visits among adults with MDD by the antipsychotic prescription status. Overall, the majority of visits were made by adults with MDD aged less than 65 years (84.5%) and female adults (66.2%). Among adults with MDD prescribed an antipsychotic, 27.0% were of racial/ethnic minority status (Table 1), which was a significantly higher proportion than among those without antipsychotic prescriptions (18.6%) (P<.001). In addition, while 42.4% of MDD patients who were prescribed an antipsychotic had Medicare or Medicaid as their primary sources of payment, only 27.6% of those without antipsychotics had such government insurance coverage (P<.001).

More than 90% of antipsychotics were prescribed in visits to psychiatrists as contrasted with other prescribers. Other clinical characteristics, such as urban metropolitan statistical area status, mental health counseling provided, and the total number of medications prescribed, were also significantly more frequent at visits in which antipsychotics were prescribed. Among those with MDD who had It is illegal to post this copyrighted PDF on any websit Table 3. Type and Prevalence of Antipsychotic Agents Among US Adults 18 Years and Older With Major Depressive Disorder (MDD) Who Were Prescribed Antipsychotics, 2006–2015 National Ambulatory Medical Care Survey

Antipsychotic Type	2006-2007	2008-2009	2010-2011	2012-2013	2014-2015	Overall (%)	P Value ^a
Typical (first-generation) agents	5.7	8.0	5.0	2.2	3.1	4.9	.253
Butyrophenones							
Haloperidol	1.7	3.8	0.4	0.0	1.5	1.6	.124
Phenothiazines							
Chlorpromazine	1.8	0.9	0.0	0.0	0.0	0.5	.587
Fluphenazine	0.6	0.0	0.0	0.0	0.9	0.3	.776
Perphenazine	1.1	0.0	2.7	0.3	0.7	1.0	.132
Prochlorperazine	0.0	1.1	0.0	0.0	0.0	0.2	.761
Thioridazine hydrochloride	0.0	0.2	0.0	0.9	0.0	0.2	.724
Trifluoperazine hydrochloride	0.5	0.4	0.0	1.0	0.0	0.3	.708
Thiothixene	0.0	1.2	1.9	0.9	0.0	0.9	.611
Miscellaneous							
Loxapine succinate	0.0	0.0	0.0	0.0	0.0	0.0	
Molindone hydrochloride	0.0	0.0	0.0	0.0	0.0	0.0	
Pimozide	0.0	0.5	0.0	0.0	0.0	0.1	.896
Atypical (second-generation) agents	96.1	95.6	96.1	98.1	98.3	96.8	.562
Aripiprazole ^b	15.9	30.9	26.1	30.5	32.9	27.7	.147
Asenapine	0.0	0.0	0.0	2.4	0.3	0.5	.321
Clozapine	0.0	1.0	0.0	0.2	0.0	0.3	.733
lloperidone	0.0	0.0	0.0	0.0	0.0	0.0	
Lurasidone	0.0	0.0	0.3	2.6	2.9	1.2	.168
Olanzapine ^b	15.8	6.0	8.3	6.5	8.5	8.7	.130
Paliperidone	0.0	0.0	2.2	2.7	0.3	1.0	.340
Quetiapine ^b	42.1	37.1	35.0	28.0	37.6	36.0	.459
Risperidone	24.6	20.9	20.8	23.4	21.2	22.0	.971
Ziprasidone ^b	3.7	7.0	6.5	5.4	2.3	5.1	.491

^aCompares proportion differences across years using a weight-corrected Pearson χ^2 statistic.

^bIndicates approved and off-label uses by the US Food and Drug Administration for MDD.

antipsychotics prescribed, 85.9% also had antidepressants prescribed. Among codiagnosed psychiatric and substance use psychiatric disorders, posttraumatic stress disorder, adjustment disorder, personality disorder, and cannabisrelated disorders were all significantly associated with receipt of antipsychotic prescriptions.

Trends of Antipsychotic Prescriptions

Table 2 shows stratified analyses of the proportion of visits in which antipsychotics were prescribed by year among adults with MDD. Overall, the percentage of visits at which antipsychotics were prescribed increased from 18.5% in 2006-2007 to 24.9% in 2008-2009, and then declined to 18.9% in 2014–2015. The antipsychotic use was particularly common for those with MDD with psychotic features, ranging from 68.4% in 2006-2007 to 75.2% in 2014-2015. Among visits with adults aged 75 years or older, the percentage receiving antipsychotic prescriptions decreased most substantially over time from 27.0% in 2006-2007 to only 10.7% in 2014-2015 (OR=0.73; 95% CI, 0.56-0.95). In cases of visits among non-Hispanic blacks and Medicare beneficiaries aged 65 years or older, the proportions of visits at which antipsychotics were prescribed fluctuated over time with no consistent trend (P = .044 and .049, respectively).

Types and Prevalence of Antipsychotic Agents

Table 3 presents types and prevalence of individual antipsychotic agents by the time period. Overall, more than

90% of commonly prescribed antipsychotics were atypical (second-generation) medications. The most commonly prescribed agents were quetiapine (36.0%), aripiprazole (27.7%), risperidone (22.0%), olanzapine (8.7%), and ziprasidone (5.1%) (not mutually exclusive), which were all atypical. The prescribing patterns for individual agents were relatively stable over time, with no significant differences across the time periods.

Multivariable Logistic Regression Analysis of Antipsychotic Prescription

Table 4 presents the results of multivariable-adjusted logistic regression model, which estimated the odds that an antipsychotic was prescribed at any given visit. Two demographic factors were associated with higher odds of antipsychotic prescription. When compared to non-Hispanic whites, both non-Hispanic blacks and Hispanics had 2.56 and 1.69 times higher odds of receiving an antipsychotic prescription, respectively (P < .01). In the case of health insurance coverage, those covered by Medicare (and aged < 65 years) and Medicaid had 2.16 and 2.06 times higher odds, respectively, of receiving an antipsychotic prescription, when compared to those with private insurance coverage (P < .01).

Turning to clinical characteristics, visits to physicians other than a psychiatrist (ie, primary care and other specialties) had 0.29 times lower odds of an antipsychotic prescription than visits to a psychiatrist (P<.001; 95% CI, **It is illegal to post this cop** Table 4. Adjusted Odds Ratios (AORs) for Antipsychotic Prescriptions Among Adults 18 Years and Older With Major Depressive Disorder, 2006–2015 National Ambulatory Medical Care Survey

incarcar care burrey		
Variable (reference group in parentheses)	AOR	95% CI
Race/ethnicity (non-Hispanic white)		
Non-Hispanic black	2.56**	1.50-4.36
Hispanic	1.69**	1.16-2.46
Other ^a	0.93	0.47-1.82
Primary source of payment (private)		
Medicare (< 65)	2.16***	1.50-3.10
Medicare (≥65)	1.16	0.77-1.76
Medicaid	2.06**	1.36-3.12
Other ^b	1.18	0.88-1.57
Repeat of visits in the past 12 months (none)		
1–2 visits	1.02	0.47-2.20
3–5 visits	1.12	0.53-2.35
6+ visits	1.64	0.79-3.42
Physician specialty (psychiatry)		
Other ^c	0.29***	0.18-0.48
Metropolitan statistical area (MSA) status		
Non-MSA	1.17	0.78-1.77
Mental health counseling provided (no)		
Yes	1.47**	1.12-1.94
Number of medications (< 3)		
3+	5.78***	4.39-7.60
Adjustment disorder (no)		
Yes	0.12**	0.02-0.60
Cannabis use disorder (no)		
Yes	2.66*	1.17-6.06
Sample size		
Unweighted sample		4,044
Weighted visits	7,9	76,941
F statistic	18.	26***

^aIncludes Asians, American Indian/Alaska Natives, Native Hawaiian or Other Pacific Islanders, and other mixed races.

^bIncludes worker's compensation, self-pay, no charge, and others.
^cIncludes primary care, general surgery, obstetrics/gynecology, orthopedic surgery, cardiovascular diseases, dermatology, urology, neurology, ophthalmology, otolaryngology, and others.

**P* < .05.

***P<.001.

0.18–0.48). Visits that included mental health counseling had 1.47 times higher odds that antipsychotics were prescribed, compared to visits with no mental health counseling (P<.01; 95% CI, 1.12–1.94). Visits with 3 or more medications prescribed had 5.78 times higher odds of an antipsychotic prescription, compared to visits with 2 or fewer medications prescribed (P<.001; 95% CI, 4.39–7.60). Finally, visits in which an adjustment disorder was diagnosed had 0.12 times lower odds that antipsychotics would be prescribed (P<.01; 95% CI, 0.02–0.60), while visits in which a cannabis use disorder was diagnosed had 2.66 times higher odds that antipsychotics would be prescribed (P<.05; 95% CI, 1.17–6.06).

DISCUSSION

This study evaluated antipsychotic prescribing trends among adults who received a diagnosis of MDD, with no comorbid psychotic disorders, in a nationally representative sample of office-based outpatient visits from 2006 to 2015. Overall, the antipsychotic prescription rate increased from 18.5% in 2006–2007 to 24.9% in 2008–2009 (when **chief PDF on any website** several antipsychotic agents received FDA approval for use in MDD), and then declined to 18.9% in 2014–2015. On the one hand, these prescribing rates are generally stable and broadly similar to those in previous studies,^{14,17} which found that 14% of nonelderly Medicaid adults with depression had antipsychotics prescribed within a year of depression onset,¹⁴ and 20.6% of VHA patients with MDD were prescribed antipsychotics.¹⁷

On the other hand, it appears that the prescribing rates of antipsychotics did increase in response to FDA approvals for use in MDD from 2007 to 2009 and decreased in elderly patients in response to subsequent findings of increased mortality in this group. The decreasing rate from 27.0% in 2006-2007 to 10.7% in 2014-2015 in adults 75 years or older may reflect physicians' responsiveness to the FDA's black-box warning concerning the increased risk of death with antipsychotics in the elderly^{24,25} and/or to other clinical guidelines such as the Beers criteria that identified potentially inappropriate medication use in older adults.²⁶ The FDA black-box warning issued in 2008 stated that both conventional and atypical antipsychotics increased a risk of mortality in older adults treated for dementiarelated psychosis.²⁵ In a similar vein, Beers criteria have recommended against the use of antipsychotics due to its increased risks of developing cognitive impairment, including dementia, and stroke among older patients.²⁶

Of the visits with antipsychotics prescribed among adults with MDD, 85.9% also had antidepressants prescribed. A previous study suggests that 71.3% of patients for whom antipsychotics for MDD were initiated did not have minimally adequate antidepressant treatment prior to the initiation of antipsychotic treatment as recommended by the FDA.¹⁴ However, due to the cross-sectional nature of our study, we were not able to identify whether such concomitant prescribing of antipsychotics followed adequate antidepressant trials or previous antidepressant switching or augmentation. Future population-based observational research should investigate this pattern to address whether the use of antipsychotics among patients with MDD in office-based outpatient settings follows recommended use in patients unresponsive to standard antidepressants.

The most commonly prescribed antipsychotic medications were quetiapine (36.0%), aripiprazole (27.7%), risperidone (22.0%), and olanzapine (8.7%), which were all second-generation medications and together accounted for more than 85% of all antipsychotic prescriptions in any given time interval. It appears that these patterns are in accordance to the FDA approvals and other clinical guidelines for antipsychotic use in the treatment of MDD.⁸⁻¹⁰ Furthermore, this trend was also similar to trends in previous studies, which showed predominant exposure of second-generation antipsychotics in patients diagnosed with MDD.^{14,17}

One key correlate of antipsychotic prescription was being a minority (ie, non-Hispanic black or Hispanic). Additional correlates suggest greater clinical severity or dysfunction, for example a predominance of patients younger than 65

^{**}P<.01

It is illegal to post this copy years covered by Medicare or by Medicaid, receiving mental health counseling in addition to pharmacotherapy, receiving 3 or more medications, or being diagnosed with comorbid cannabis use disorders.¹⁷ Future research is needed to determine why racial/ethnic minority adults were more likely to receive antipsychotics. Predictors associated with the decreased likelihood of antipsychotic prescription were visits to specialties other than psychiatry and having been diagnosed with adjustment disorders, suggestive of less severe clinical status.

There are 2 notable clinical implications from this study. This is the first study to investigate patterns of antipsychotic prescribing among adults with MDD in office-based outpatient settings, and it found that antipsychotics were prescribed in 1 in 5 visits for MDD with limited change over time. While the recent VAST-D study¹⁰ provided robust support for the greater effectiveness of augmentation with aripiprazole and perhaps other antipsychotics than switching to or augmenting treatment with another antidepressant, further studies are needed to address the balance of effectiveness, safety, and cost-effectiveness. Further planned analyses of data from VAST-D should provide some of this information, especially with respect to effects on elderly patients, at greatest risk for adverse events. Second, it will be important to assess increasing antipsychotic prescribing in adults with MDD with either aripiprazole or other antipsychotics in response to the findings of VAST-D. While FDA approval seems to have had limited impact on

anted PDF on any website. use of this approach, the likely impact of publication of a major comparative effectiveness trial for MDD is currently unknown and deserves future study.

There are several limitations of this study. First, NAMCS does not capture outpatient visits to hospital-affiliated clinics and emergency departments, which account for about 8.5% of all outpatient visits.¹² Furthermore, NAMCS excludes prescriptions ordered by phone. Second, NAMCS collected patient information in a randomly selected visit, which may have resulted in incomplete documentation of the patient services. For example, NAMCS cannot identify if patients with MDD received antipsychotic prescriptions at a different clinic. For these reasons, our findings may underestimate the magnitude of antipsychotic prescribing patterns. Third, the NAMCS does not collect dosing information (eg, strength and duration) of each drug. This limits the ability to investigate appropriate or potentially inappropriate use of antipsychotics in adults with MDD.

Despite these limitations, this study shows that antipsychotics have been prescribed at 1 in 5 office-based outpatient visits at which MDD was diagnosed, with general stability over time except in the elderly. Most prescribed antipsychotic medications were second-generation agents, in accordance with FDA approvals and other clinical guidelines. Yet, the degree of appropriate use and the impact of a recent landmark effectiveness trial supporting the use of antipsychotics in treating MDD are as yet unknown, and this study should spur additional research.

2003;53(8):649-659.

pdf.

8. Department of Veterans Affairs and

Department of Defense. VA/DoD clinical

major depressive disorder. 2016. VA.gov

9. Patkar AA, Pae CU. Atypical antipsychotic

major depressive disorder. CNS Drugs.

2013;27(suppl 1):S29-S37.

augmentation strategies in the context of

guideline-based care for the treatment of

10. Mohamed S, Johnson GR, Chen P, et al. Effect

on remission among patients with major

depressive disorder unresponsive to

randomized clinical trial. IAMA.

11. Nelson JC, Papakostas GI. Atypical

Psychiatry. 2009;166(9):980-991.

12. Philip NS, Carpenter LL, Tyrka AR, et al.

2017;318(2):132-145.

2010;11(5):709-722.

antidepressant treatment: the VAST-D

antipsychotic augmentation in major

depressive disorder: a meta-analysis of

placebo-controlled randomized trials. Am J

Pharmacologic approaches to treatment

modern era. Expert Opin Pharmacother.

resistant depression: a re-examination for the

of antidepressant switching vs augmentation

practice guideline for the management of

website. https://www.healthquality.va.gov/

guidelines/MH/mdd/MDDFullFinal5192016.

Submitted: October 16, 2017; accepted December 7. 2017.

Published online: February 13, 2018.

Author contributions: Study concept and design: Drs Rhee and Rosenheck; data acquisition and statistical analyses: Dr Rhee; interpretation of data: all authors; drafting of manuscript: Drs Rhee and Rosenheck; critical revision of manuscript for important intellectual content: all authors: supervision: Dr Rosenheck: data access and responsibility: Dr Rhee had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Potential conflicts of interest: Each author reported no financial or other relationship relevant to this article.

Funding/support: Dr Rhee received funding support from the National Institutes of Health (NIH) (no. T32AG019134).

Role of the sponsor: The funding agency, NIH, had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.

Disclaimer: Analyses, interpretations, and conclusions are solely those of the authors and do not necessarily reflect the views of the Division of Health Interview Statistics or NCHS of the CDC.

Additional information: This article does not contain any studies with human participants or animals performed by the authors. All research procedures performed in this study are in accordance with the ethical standards of the Institutional Review Board at Yale University School of Medicine (no. 2000021850). Publicly available data were obtained from the National Center for

Health Statistics, Centers for Disease Control and Prevention (https://www.cdc.gov/nchs/ahcd/ index.htm).

REFERENCES

- 1. Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. HHS Publication No. SMA 16-4984, NSDUH Series H-51. SAMHSA website. https://www. samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/ NSDUH-FFR1-2015.htm#mhi. 2016.
- 2. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015:23(1):1–21.
- 3. World Health Organization. Depression: fact sheet. WHO website. http://www.who.int/ mediacentre/factsheets/fs369/en/. 2017.
- 4. Rhee TG, Schommer JC, Capistrant BD, et al. Potentially inappropriate antidepressant prescriptions among older adults in officebased outpatient settings: national trends from 2002 to 2012 [published online ahead of print July 20, 2017]. Adm Policy Ment Health.
- 5. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200.
- 6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006:163(11):1905-1917.
- 7. Fava M. Diagnosis and definition of treatmentresistant depression. Biol Psychiatry.

13. Han C, Wang SM, Kato M, et al. Second-

- generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother, 2013;13(7):851-870.
- 14. Gerhard T, Stroup TS, Correll CU, et al. Antipsychotic medication treatment patterns in adult depression [published online ahead of print July 5, 2017]. J Clin Psychiatry.
- 15. Mohamed S, Johnson GR, Vertrees JE, et al. The

Rhee et al program]. College website. https://www.cdo VA Augmentation and Switching Treatments

for Improving Depression Outcomes (VAST-D) study: rationale and design considerations. Psychiatry Res. 2015;229(3):760-770.

- 16. Spina E, Trifirò G. Pharmacovigilance in Psychiatry. New York, NY: Springer Berlin Heidelberg; 2015.
- 17. Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the US Department of Veterans Affairs. J Clin Psychiatry. 2009;70(6):906-912.
- 18. National Center for Health Statistics. Ambulatory health care data. CDC website. https://www.cdc.gov/nchs/ahcd/index.htm. 2017.
- 19. National Center for Health Statistics. Ambulatory health care data: questionnaires, datasets, and related documentation. CDC

questionnaires.htm. 2017.

- 20. American Society of Health-System Pharmacists. American Hospital Formulary Service (AHFS) Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2017.
- 21. Bhalla IP, Stefanovics EA, Rosenheck RA. Clinical epidemiology of single versus multiple substance use disorders: polysubstance use disorder. Med Care. 2017;55(suppl 9 suppl 2):S24-S32.
- 22. Rhee TG, Capistrant BD, Schommer JC, et al. Effects of depression screening on diagnosing and treating mood disorders among older adults in office-based primary care outpatient settings: an instrumental variable analysis. Prev Med. 2017;100:101-111.
- 23. Stata Statistical Software: Release 13 [computer

2013.

- 24. US Food and Drug Administration. Information on conventional antipsychotics. FDA website. https://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatients andProviders/ucm107211.htm. 2008. Accessed October 1, 2017.
- 25. US Food and Drug Administration. Information for Healthcare Professionals: Conventional Antipsychotics. FDA website. https://www.fda. gov/Drugs/DrugSafety/ucm124830.htm. 2008. Accessed October 9, 2017.
- 26. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246.